Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Mathematical model reveals how cell turnover determines the success of adaptive therapy

One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.

17 Feb 2021

New model predicts which patients will gain most from PSMA PET scan

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.

16 Feb 2021

New urine test could avoid unnecessary prostate cancer biopsies

A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients.

11 Feb 2021

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

11 Feb 2021

Researchers analyze overall survival rate of prostate cancer patients treated with melatonin

Oncotarget recently published "Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment" which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019.

11 Feb 2021

Study reveals why Black men with prostate cancer have greater survival benefits from immunotherapy

Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from immunotherapy treatment.

10 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

Researchers from Hong Kong Baptist University and the Faculty of Medicine at The Chinese University of Hong Kong have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive and more reliable method for the diagnosis of prostate cancer.

8 Feb 2021

Cancer patients less likely to receive life-saving therapy when suffering a heart attack

A major study of nearly 2 million heart attack patients has found that many who also had cancer were not offered a potentially lifesaving treatment, despite the fact it had major benefits.

4 Feb 2021

New process separates beneficial glucocorticoids from unwanted side-effects

A collaboration led by Scripps Research has developed a way to separate the beneficial anti-inflammatory properties of a group of steroids called glucocorticoids from some of their unwanted side-effects, through an optimization process they named "ligand class analysis."

3 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

27 Jan 2021

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

One common challenge of cancer therapy is when cancer cells don't respond to a drug that is usually able to kill or weaken them, known as treatment resistance.

26 Jan 2021

Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors

The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.

26 Jan 2021

Five-day regimen of radiotherapy safe, effective for men with high-risk forms of prostate cancer

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.

26 Jan 2021

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Mathematical model reveals how cell turnover determines the success of adaptive therapy

New model predicts which patients will gain most from PSMA PET scan

New urine test could avoid unnecessary prostate cancer biopsies

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

Researchers analyze overall survival rate of prostate cancer patients treated with melatonin

Study reveals why Black men with prostate cancer have greater survival benefits from immunotherapy

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

Cancer patients less likely to receive life-saving therapy when suffering a heart attack

New process separates beneficial glucocorticoids from unwanted side-effects

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors

Five-day regimen of radiotherapy safe, effective for men with high-risk forms of prostate cancer

Dramatic changes seen in delivery of radiotherapy treatments during coronavirus pandemic

New technique can rapidly diagnose prostate cancer from urine

New tests may help improve the selection of men considering prostate cancer surveillance

Researchers discover unexpected role for the clock gene in prostate cancer progression

Scientists identify bacteria-based approach against cancer

What to know about prostate cancer eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in